mesocorticolimbic system
Recently Published Documents


TOTAL DOCUMENTS

55
(FIVE YEARS 10)

H-INDEX

17
(FIVE YEARS 2)

2022 ◽  
pp. 91-102
Author(s):  
Yolanda Campos-Jurado ◽  
Javier Cuitavi ◽  
Natalia Landsberg ◽  
Jesús D. Lorente ◽  
Lucia Hipólito

2021 ◽  
Author(s):  
Stefania Ferraro ◽  
Jean Paul Medina ◽  
Anna Nigri ◽  
Luca Giani ◽  
Greta Demichelis ◽  
...  

BACKGROUND: Converging evidence suggests that anatomical and functional mesocorticolimbic abnormalities support the chronicization of pain disorders. METHODS: We mapped structural and functional alterations of the mesocorticolimbic system in a sample of chronic cluster headache (cCH) patients (n = 28) in comparison to age and sex-matched healthy individuals (n=28) employing structural MRI and resting-state functional MRI (rs-fMRI). RESULTS: Univariate logistic regression models showed that several of the examined structures/areas (i.e., the bilateral nucleus accumbens, ventral diencephalon, hippocampus, and frontal pole, and the right amygdala) differentiated cCH patients from healthy individuals (p<0.05, uncorrected). Specifically, all the significant structures/areas had increased volumes in cCH patients compared to healthy individuals. The examination of the groups suffering from left and right-sided cranial attacks showed a lateralization effect: ipsilateral to the pain ventral diencephalic regions and contralateral to the pain nucleus accumbens discriminated cCH patients from healthy individuals. The rs-fMRI data analyses showed that cCH patients compared to CTRL individuals present robust reduced functional connectivity in the right frontal pole-right amygdala pathway (p<0.05, FDR-corrected). CONCLUSION: Our results showed that cCH patients present anatomical and functional maladaptation of the mesocorticolimbic system, with functional data indicating a possible prefrontal areas' failure to modulate the mesolimbic structures. These results were opposite to what we hypothesized based on the previous literature on chronic pain conditions. Future studies should assess whether the observed mesocorticolimbic abnormalities are due to the neuroprotective effects of the assumed medications, or to the frequent comorbidity of CH with neuropsychiatric disorders or if they are a genuine neural signature of CH and/or cCH condition.


2021 ◽  
Vol 12 ◽  
Author(s):  
Javier Cuitavi ◽  
Jesús David Lorente ◽  
Yolanda Campos-Jurado ◽  
Ana Polache ◽  
Lucía Hipólito

Evidence concerning the role of alcohol-induced neuroinflammation in alcohol intake and relapse has increased in the last few years. It is also proven that mu-opioid receptors (MORs) mediate the reinforcing properties of alcohol and, interestingly, previous research suggests that neuroinflammation and MORs could be related. Our objective is to study neuroinflammatory states and microglial activation, together with adaptations on MOR expression in the mesocorticolimbic system (MCLS) during the abstinence and relapse phases. To do so, we have used a sex-dependent rat model of complete Freund’s adjuvant (CFA)-induced alcohol deprivation effect (ADE). Firstly, our results confirm that only CFA-treated female rats, the only experimental group that showed relapse-like behavior, exhibited specific alterations in the expression of phosphorylated NFκB, iNOS, and COX2 in the PFC and VTA. More interestingly, the analysis of the IBA1 expression revealed a decrease of the microglial activation in PFC during abstinence and an increase of its expression in the relapse phase, together with an augmentation of this activation in the NAc in both phases that only occur in female CFA-treated rats. Additionally, the expression of IL1β also evidenced these dynamic changes through these two phases following similar expression patterns in both areas. Furthermore, the expression of the cytokine IL10 showed a different profile than that of IL1β, indicating anti-inflammatory processes occurring only during abstinence in the PFC of CFA-female rats but neither during the reintroduction phase in PFC nor in the NAc. These data indicate a downregulation of microglial activation and pro-inflammatory processes during abstinence in the PFC, whereas an upregulation can be observed in the NAc during abstinence that is maintained during the reintroduction phase only in CFA-female rats. Secondly, our data reveal a correlation between the alterations observed in IL1β, IBA1 levels, and MOR levels in the PFC and NAc of CFA-treated female rats. Although premature, our data suggest that neuroinflammatory processes, together with neural adaptations involving MOR, might play an important role in alcohol relapse in female rats, so further investigations are warranted.


2021 ◽  
Author(s):  
Ryan J Tomm ◽  
Desiree R Seib ◽  
George V Kachkovski ◽  
Helen R Schweitzer ◽  
Daniel J Tobiansky ◽  
...  

Androgens regulate behavioural flexibility, which is essential to adapt to a changing environment and depends on the medial prefrontal cortex (mPFC). Testosterone (T) administration decreases behavioural flexibility. It is well known that T is produced in the gonads, but T is also produced in the mesocorticolimbic system, which modulates behavioural flexibility. It is unclear how T produced in the brain versus the gonads influences behavioural flexibility. Here, we assess the effects of the androgen synthesis inhibitor abiraterone acetate (ABI) and long-term gonadectomy (GDX) on behavioural flexibility in two paradigms. In Experiment 1, ABI independent of GDX reduced the number of trials to criterion and perseverative errors in a strategy set-shifting task. Similarly, in Experiment 2, ABI but not GDX reduced perseverative errors in a reversal learning task. In subjects from Experiment 1, we also examined tyrosine hydroxylase immunoreactivity (TH-ir), and ABI but not GDX increased TH-ir in the mPFC. Our findings suggest that neurally-produced androgens modulate behavioural flexibility via modification of dopamine signalling in the mesocorticolimbic system. These results suggest novel roles for neurosteroids and possible side effects of ABI treatment for prostate cancer.


Neuropeptides ◽  
2021 ◽  
pp. 102184
Author(s):  
Ali Birdogan ◽  
Elif Salur ◽  
Fulya Tuzcu ◽  
Ramazan C. Gokmen ◽  
Meliha Ozturk Bintepe ◽  
...  

2020 ◽  
Vol 105 (6) ◽  
pp. 1012-1024
Author(s):  
Houda Nashawi ◽  
Tyler J. Gustafson ◽  
Elizabeth G. Mietlicki‐Baase

2020 ◽  
Vol 120 ◽  
pp. 104689
Author(s):  
Katelyn L. Low ◽  
Ryan J. Tomm ◽  
Chunqi Ma ◽  
Daniel J. Tobiansky ◽  
Stan B. Floresco ◽  
...  

2019 ◽  
Vol 183 ◽  
pp. 22-31 ◽  
Author(s):  
Ana Martín-Sánchez ◽  
Vincent Warnault ◽  
Sandra Montagud-Romero ◽  
Antoni Pastor ◽  
Neus Mondragón ◽  
...  

2019 ◽  
Vol 364 ◽  
pp. 193-204 ◽  
Author(s):  
Gerard M. Moloney ◽  
Wesley E.P.A. van Oeffelen ◽  
Feargal J. Ryan ◽  
Marcel van de Wouw ◽  
Caitlin Cowan ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document